Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...

FDA approval was based on the AcT noninferiority trial that found tenecteplase (at 0.25 mg/kg) to be at least on par with alteplase for safety and efficacy in acute ischemic stroke in Canadians ...

All Remote - GitLab Inc., , the most comprehensive AI-powered DevSecOps platform, today announced that GitLab Chief Financial Officer Brian Robins will present at the 2025 Cantor Fitzgerald Global ...

The fibrin-specific plasminogen activator – which is already sold as Metalyse and TNKase for patients with suspected acute myocardial infarction – was being tested in phase 3 stroke trials ...

Activase/TNKase sales came in at CHF 1.2 billion, up 5%. Sales of blood cancer drug Polivy surged 39% to CHF 1.1 billion. Blood cancer drug Gazyva/Gazyvaro’s sales totaled CHF 910 million ...

including a powerful treatment using clot-dissolving drugs such as TNKase (tenecteplase) and other kinds of tissue plasminogen activator drugs. This treatment is effective if the stroke is quickly ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

In 2025, seniors will pay less for 64 medications if they get them through Medicare Part B, which covers outpatient care, including drugs that are administered at a doctor’s office. The price ...